Table 1.
Baseline characteristics of 15 patients with TDF-induced proximal tubulopathy at the time of diagnosis
| Characteristics | Values |
|---|---|
| Mean age, years (range) | 56 (38–76) |
| Male gender, n (%) | 12 (80) |
| Body Mass Index, Kg/m2, mean (SD) | 23.2 (4.0) |
| Caucasian, n (%) | 11 (73) |
| Hypertension, n (%) | 9 (60) |
| Diabetes mellitus, n (%) | 6 (40) |
| HCV infection, n (%) | 3 (20) |
| Current smoker, n (%) | 10 (67) |
| Duration of TDF use, months mean (range) | 64 (28–103) |
| Baseline serum creatinine, mg/dL Mean (SD)(prior to TDF initiation) | 0.8 (0.2) |
| Baseline eGFR, mL/min/1.73 m2 mean (SD) (prior to TDF initiation) | 104 (17.0) |
| Serum creatinine, mg/dL mean (SD) (at the time of TDF discontinuation) | 1.22 (0.3) |
| eGFR, mL/min/1.73 m2 mean (SD) (at the time of TDF discontinuation) | 69 (19.0) |
| Change in eGFR from baseline/1.73 m2, mean (SD) | 35 (18.4) |
| Serum phosphate, mg/dL mean (SD) | 2.3 (0.7) |
| Serum potassium, mg/dL mean (SD) | 3.9 (0.6) |
| Serum bicarbonate, mg/dL mean (SD) | 24.5 (3.2) |
| FEphos, %, mean (range) | 34 (20–62) |
| TmP/GFR, mean (range) | 1.6 (0.6–2.8) |
| Glycosuria, n (%) | 7 (46) |
eGFR, estimated GFR; FEphos, fractional excretion of phosphate; TDF, tenofovir disoproxil fumarate; TmP, tubular maximal reabsorption of phosphate.